2019
Low-Risk Thyroid Cancer in Elderly: Total Thyroidectomy/RAI Predominates but Lacks Survival Advantage
Zambeli-Ljepović A, Wang F, Dinan MA, Hyslop T, Roman SA, Sosa J, Scheri RP. Low-Risk Thyroid Cancer in Elderly: Total Thyroidectomy/RAI Predominates but Lacks Survival Advantage. Journal Of Surgical Research 2019, 243: 189-197. PMID: 31185435, PMCID: PMC6773493, DOI: 10.1016/j.jss.2019.05.029.Peer-Reviewed Original ResearchConceptsDisease-specific survivalPapillary thyroid cancerExtent of surgeryTotal thyroidectomyTumor sizeThyroid cancerLow-risk papillary thyroid cancerEnd Results-Medicare databaseLow-risk thyroid cancerOlder adultsNational treatment patternsRadioactive iodine administrationUnderwent total thyroidectomyLarger tumor sizeMultivariable logistic regressionQuality of lifeMost older adultsPostoperative RAIRAI administrationCompletion thyroidectomyExcellent prognosisOlder patientsExtensive surgeryFavorable prognosisMedian age
2018
Initial Adoption of Recombinant Human Thyroid-Stimulating Hormone Following Thyroidectomy in the Medicare Thyroid Cancer Patient Population
Dinan MA, Li Y, Reed SD, Sosa JA. Initial Adoption of Recombinant Human Thyroid-Stimulating Hormone Following Thyroidectomy in the Medicare Thyroid Cancer Patient Population. Endocrine Practice 2018, 25: 31-42. PMID: 30383499, DOI: 10.4158/ep-2018-0253.Peer-Reviewed Original ResearchMeSH KeywordsAgedHumansIodine RadioisotopesMedicareRecombinant ProteinsRetrospective StudiesThyroid NeoplasmsThyroidectomyThyrotropinUnited StatesConceptsRecombinant human thyroid-stimulating hormoneHuman thyroid-stimulating hormoneThyroid-stimulating hormoneMultivariable analysisPatient populationUse of rhTSHLower inpatient costsMean outpatient costsDistant metastatic diseaseDifferentiated thyroid cancerEmergency department visitsRadioactive iodine administrationCancer patient populationSEER-Medicare dataCostly hospital staysTotal inpatient daysHealthcare Common Procedure Coding SystemTotal Medicare paymentsNumber of outpatientsMedicare patient populationPositron emission tomographySimilar overall costsRAI administrationHospital stayMultiple comorbidities
2015
Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer
Ruel E, Thomas S, Dinan MA, Perkins JM, Roman SA, Sosa JA. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer. Endocrine 2015, 52: 579-586. PMID: 26708045, PMCID: PMC4880494, DOI: 10.1007/s12020-015-0826-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinomaCarcinoma, PapillaryCombined Modality TherapyDatabases, FactualFemaleHumansIodine RadioisotopesKnowledgeLymph NodesLymphatic MetastasisMaleMiddle AgedPostoperative PeriodPrognosisRadiotherapy DosageRisk FactorsSurvival AnalysisThyroid Cancer, PapillaryThyroid NeoplasmsThyroidectomyConceptsNegative lymph nodesPapillary thyroid cancerLow-risk papillary thyroid cancerLymph nodesCN0 patientsRAI useThyroid cancerPostoperative radioactive iodine administrationTrue nodal statusExcised lymph nodesLow-risk patientsLymph node statusRadioactive iodine administrationNegative surgical marginsOdds of receiptSurgical pathology specimensCut-point analysisPN0 patientsPN0 statusPostoperative RAIRAI administrationCervical lymphMultivariable adjustmentTotal thyroidectomyNodal statusPatterns of Use and Cost for Inappropriate Radioactive Iodine Treatment for Thyroid Cancer in the United States: Use and Misuse
Goffredo P, Thomas SM, Dinan MA, Perkins JM, Roman SA, Sosa JA. Patterns of Use and Cost for Inappropriate Radioactive Iodine Treatment for Thyroid Cancer in the United States: Use and Misuse. JAMA Internal Medicine 2015, 175: 638-640. PMID: 25686394, DOI: 10.1001/jamainternmed.2014.8020.Peer-Reviewed Original ResearchAdjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer
Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 1529-1536. PMID: 25642591, PMCID: PMC4399282, DOI: 10.1210/jc.2014-4332.Peer-Reviewed Original ResearchConceptsRadioactive iodine therapyPapillary thyroid cancerIntermediate-risk papillary thyroid cancerAdjuvant radioactive iodine therapyIntermediate-risk PTC patientsImproved overall survivalIntermediate-risk patientsOverall survivalRisk of deathRAI therapyIodine therapyPTC patientsThyroid cancerAmerican Thyroid Association riskLong-term prognosisAmerican Joint CommissionCommon endocrine malignancyPaucity of dataTotal thyroidectomyAdult patientsMultivariate adjustmentClinical factorsAggressive variantStage T3Patient group